JB Chemicals &Pharmaceuticals’ shares soared over 5% to hit a fresh 52-week high of Rs 1,536.25 a day after the company posted a 36% surge in profit after tax at Rs 151 crore in the second quarter of FY25 compared to Rs 111 crore in Q2FY23. The company’s revenue in the quarter under review stood at Rs 882 crore, as against Rs 809 crore in the corresponding period a year ago, JB Chemicals & Pharmaceuticals said in a statement.
JB Chemicals & Pharmaceuticals have been on a winning streak, treating investors with impressive returns over the last one year. The share price has gained 8.29% in the last five days, 3.55% in the last one month, 47.50% in the last six months and a whopping 55.18% year to date.
Also Read
Alkem Laboratories posts buoyant growth in Q2; Should you buy, hold or sell the stock?
Should you buy, sell or hold JB Pharma’s shares?
Jefferies: Buy – Target Price: 1680
“JB Pharma’s 2QFY24 EBITDA was 8% above estimates despite 2% revenue miss due to superior gross margins and lower opex. India sales grew 11% YoY led by 18% YoY growth in chronic sales (52% of India sales). Strong India and CDMO outlook coupled with gradual margin improvement from improving chronic mix and field force productivity keep us positive. We raise FY24-26E EPS by 4-7% and Target Price to Rs 1,680 from Rs 1,555. Maintain ‘Buy’.”
Market rally leads to higher regulatory fees for stock exchanges Multibagger SJVN jumps 8% after Q1 net profit zooms 31% RBI likely to maintain status quo, unlikely to cut rates before September Indexed ad volumes per Channel on TV dropped 3% in H1,2024 compared to the same period of previous year, reveals TAM report
Prabhudas Lilladher: Buy – Target Price : Rs 1675
“We believe JB Chemicals & Pharmaceuticals will continue with its growth momentum driven by 1) geographical expansion of legacy brands 2) improvement in MR productivity 3) scale up in Sanzyme, Azmarda and Razel franchise 4) launch of new products & therapies 5) scaling up contract manufacturing business and 6) improvement in FCF generation. Our FY24/25E EPS stands broadly remains unchanged. We expect EPS CAGR of 29% over FY23-26E. At CMP, the stock is trading at 27x FY25E P/E adjusted for ESOP and amortization charges. We maintain our ‘BUY’ rating with revised Target Price of Rs 1,675/share (Rs 1,500 earlier), valuing at 30x Sept 2025E EPS adjusted for ESOP and amortization charges.”
(The recommendations in this story are by the respective research analysts and brokerage firms. FinancialExpress.com does not bear any responsibility for their investment advice Come from Sports betting site VPbet . Capital markets investments are subject to rules and regulations. Please consult your investment advisor before investing.)
Related Posts
Players love invading each other's personal space and getting in each other's way, and so creating multiplayer tablet games in which players are forced to play in close proximity can lead to some great experiences. As part of his talk at GDC Europe today, Slamjet Stadium developer Alistair Aitcheson discussed the possibilities of creating m…
Read moreEA has announced that Plants Vs Zombies 3 will no longer be playable from November 15, with the publisher removing the game from app stores today so that it can undergo "a major overhaul".
The tower defense threequel soft launched in January, but received an unenthusiastic response from players…
Read moreGenerative AI has been the epicenter of conversation about the future of entertainment across movies, TV, music, and video games. With more studios and developers embracing the technology, despite an ongoing voice-actor strike and even Robert Downey Jr. planning to sue anyone who uses his likeness. A Netflix executive is doubling down on using generative AI for video game development, even afte…
Read moreI was blown away when I first played Shadows of Doubt last year. The detective sim realizes a city of characters, each with their own routines, jobs, and lives to live, and you’re dropped into the middle of the locale to solve crimes while you chase down a serial killer. As far as the genre of immersive sims goes, this one seemed to have a lot going for it even while it was in Steam Early Acces…
Read moreAmazon Prime members have a diverse selection of retro-flavored games to look forward to in February, as nuclear wasteland exploration, space-blasting action, and an old-fashioned murder mystery will be available to claim for free through the Prime Gaming hub.
Fallout and Breakout: Recharged kick things off at the beginning of the month. The original Fallout is still a fascinating journey…
Read moreIn a major policy reversal, Apple has announced it is opening its App Store up to game-streaming services. This marks a big win for companies like Microsoft and Nvidia–both of which offer game streaming services that were previously only accessible on iPhones via browser–as well as consumers, who will theoretically be able to access programs like Xbox Cloud Streaming through a designated app.…
Read moreHave you ever seen a hacker portrayed in the media and thought, despite the fact that they’re doing something malicious, that the actual process of hacking seems pretty cool? It’s hard not to. It’s appealing to imagine a single person–using only their wits and their knowledge of technology–going up against a company or agency with hundreds of employees and coming out on top. Unfortunately, bu…
Read moreNintendo has announced that F-Zero X will be joining Nintendo Switch Online’s Expansion Pack on March 11. Sharing the announcement on Twitter, the publisher confirmed that the F-Zero X will be released for the Nintendo 64 collection and will allow online cooperative play with up to three other friends.
The game takes place in the year 2560 where “the greatest racing co…
Read moreLupin, a leading pharmaceutical company, witnessed a sharp decline in its share price, dropping more than 6% during morning trades on Tuesday, subsequent to the release of its Q4 earnings performance reported on Monday post-market hours. The shares of Lupin dipped by 6.11%, reaching an intra-day low of Rs 1,581.10 per share on the NSE.
Lupin Ltd reported a net profit of Rs 359.4 Cro…
Read moreThe markets ended in green zone after a volatile session on Monday. The Nifty closed flat at 19,674 while the Sensex finished Monday’s session at 66,023, up merely 14 points. Sectors such as realty, banking and consumer durables performed well while IT and Pharma counters struggled. The market breadth is poised evenly with the Nifty Advances -Decline ratio maintained at 1:1.
A…
Read more